Results 1 to 10 of about 2,626 (203)

Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a common chronic inflammatory disease during adolescence, with severe forms having a particularly high impact on patients’ quality of life.
Pilar Villodre Lozano, Tania Díaz Corpas, Altea Esteve Martínez, Fernando Millán Parrilla, Montserrat Évole Buselli, Jose María Martín Hernández, Laura Berbegal de Gracia, Francisco Javier Melgosa Ramos, Javier Auban Pariente, Javier Sánchez Arraez   +9 more
doaj   +4 more sources

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study [PDF]

Acta Dermato-Venereologica
Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce.
Laura Calabrese, Elisa Cinotti, Martina D’Onghia, Alessandra Cartocci, Pietro Rubegni, François Maccari , Claire Boulard, Ziad Reguiai, Pierre-André Becherel, Caroline Jacobzone, Edouard Begon, Charlotte Fite, Beatrice Walls, Anne Laure Liegeon, Josiane Parier, Guillaume Chaby, Jean-Luc Perrot   +16 more
doaj   +5 more sources

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study [PDF]

Dermatology and Therapy
Introduction Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial.
Tiago Torres, Jensen Yeung, Vimal H. Prajapati, Simone Ribero, Anna Balato, Angelo Valerio Marzano, Maria João Cruz, Maria João Paiva Lopes, Elizabeth Lazaridou, Jose-Manuel Carrascosa, José Miguel Alvarenga, Pedro Farinha, Bruno Duarte, Monica Munera-Campos, Siddhartha Sood, Brian D. Rankin, Michela Ortoncelli, Stefano Caccavale, Silvia Mariel Ferrucci, Gilberto Pires Rosa, Athina Ioanna Daponte, Gianmarco Silvi, Ketty Peris, Niccolò Gori, Francesca Prignano, Antonio Kolios, Pedro Herranz, Stamatios Gregoriou, Natalia Rompoti, Spyridon Gkalpakiotis, Andrea Chiricozzi   +30 more
doaj   +4 more sources

Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database [PDF]

Frontiers in Immunology
ObjectivesDupilumab and tralokinumab are FDA-approved biological agents for the treatment of atopic dermatitis (AD). This study analyzed tralokinumab-related adverse events (AEs) reported by healthcare professionals, utilizing data mined from the FDA ...
Yueping Jiang, Xinjuan Sun, Yang Li
doaj   +2 more sources

Tralokinumab: First Approval [PDF]

Drugs, 2021
Tralokinumab (Adtralza®) is a human IgG4 monoclonal antibody being developed by LEO Pharma for the treatment of atopic dermatitis. The T-helper cytokine IL-13 is thought to play a key role in the pathogenesis of atopic dermatitis. Tralokinumab specifically binds with high affinity to IL-13, inhibiting its interaction with the IL-13 receptor and thereby
exaly   +3 more sources

Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease, and patients with moderate-to-severe AD may require treatment with biologics in combination with topical corticosteroids (TCS).
Marni Wiseman, Marco Benvenuto, Liv Strømkjær, Asger Paludan-Müller, Lasse Ryttig, Anne Sohrt Petersen, Andreas Wollenberg   +6 more
doaj   +2 more sources

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic skin disease largely driven by interleukin (IL)-13, which is targeted by tralokinumab and lebrikizumab.
Matthias Augustin, April Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres   +6 more
doaj   +2 more sources

Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab [PDF]

Dermatology Practical & Conceptual
Introduction: The advent of biotechnological drugs has significantly changed the management of atopic dermatitis (AD) and the approach to the moderate-to-severe form of this chronic relapsing disease.
Annunziata Dattola, Martina Tolone, Emanuele Amore, Luigi Bennardo, Simone Amato, Teresa Grieco, Antonio Giovanni Richetta, Giovanni Pellacani, Nevena Skroza, Steven Paul Nisticò   +9 more
doaj   +3 more sources

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA) [PDF]

Dermatology and Therapy
Introduction The tralokinumab pre-filled pen was developed to improve patient convenience and deliver 300 mg tralokinumab (the recommended dose for most patients) with one injection.
Jennifer Soung, Vivian Laquer, Matthew Zirwas, Peter van Iperen, John C. Stinson, Katrine Lykke Albertsen, Linda Stein Gold   +6 more
doaj   +2 more sources

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring continuous therapy. The objective with the ECZTEND trial was to assess the long-term safety and efficacy of tralokinumab treatment.
Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich   +15 more
doaj   +2 more sources